testis specific protein Y-linked 22, pseudogeneGenealiases: []
Q-omics provides the consensus-scored TSPY22P profile across patient tissues and cancer cell-line models. TSPY22P expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TSPY22P is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, TSPY22P RNA expression shows 5,063 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LIHC, LUAD, and COAD as cancer lineages where TSPY22P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPY22P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPY22P survival associations across molecular data types. TSPY22P RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPY22P RNA expression–survival associations across cancer types. High TSPY22P expression shows unfavorable associations in LIHC, SKCM, ESCA, LUAD and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TSPY22P RNA expression.
This table summarizes TSPY22P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TSPY22P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPY22P shows lower tumor expression in LUAD. The LUAD box plot shows higher TSPY22P RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p = .016).
This table shows molecular features associated with TSPY22P in patient tissues and cancer cell lines. In patient samples, TSPY22P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
